Literature DB >> 32523634

Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update.

Shuang Liu1, Mingwei Tang1, Yihan Cao2, Chen Li3.   

Abstract

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a spectrum of heterogeneous diseases characterized by osteoarticular and dermatological manifestations. Osteitis and hyperostosis are core clinical manifestations in SAPHO syndrome, typically affecting multiple areas and possibly progressing to irreversible osteoarticular damage. Most patients with SAPHO have cutaneous involvement, mainly manifested as palmoplantar pustulosis and severe acne. Systemic manifestations are uncommon but occasionally reported. Epidemiological studies suggest the annual prevalence of SAPHO syndrome varies from 0.00144 in 100,000 in Japanese individuals to fewer than 1 in 10,000 in White individuals. The precise etiopathogenesis of SAPHO remains unclear, but it is generally considered an autoinflammatory syndrome that may be related to various etiologies, such as immune dysfunction, infection and genetic predisposition. Owing to the relapsing-remitting disease course, the goal of management is to improve clinical symptoms and prevent disease progression. Various treatments, including nonsteroidal anti-inflammatory drugs, conventional disease-modifying antirheumatic drugs, bisphosphonates, biologics, and antibiotics, are promising options for alleviating the disease.
© The Author(s), 2020.

Entities:  

Keywords:  SAPHO syndrome; diagnosis; etiology; imaging; treatment

Year:  2020        PMID: 32523634      PMCID: PMC7236399          DOI: 10.1177/1759720X20912865

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  12 in total

1.  Imaging Manifestation of Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis Syndrome.

Authors:  Asma AlHatmi; Sameer B Raniga
Journal:  Sultan Qaboos Univ Med J       Date:  2022-05-26

2.  [SAPHO syndrome : An overview and nosological differentiation of 35 disease cases].

Authors:  Philipp Klemm; Uwe Lange
Journal:  Z Rheumatol       Date:  2021-03-16       Impact factor: 1.372

3.  Thoracic outlet syndrome in a patient with SAPHO syndrome - A case report.

Authors:  H Ohida; C Curuk; H Prescher; E Stegemann; Th Bürger
Journal:  Int J Surg Case Rep       Date:  2021-02-25

4.  Serum-derived extracellular vesicles inhibit osteoclastogenesis in active-phase patients with SAPHO syndrome.

Authors:  Yanpan Gao; Yanyu Chen; Lun Wang; Chen Li; Wei Ge
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-04-16       Impact factor: 5.346

Review 5.  Dermatology: how to manage acne vulgaris.

Authors:  Alexander Kc Leung; Benjamin Barankin; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2021-10-11

6.  The value of multi-modality imaging in establishing the diagnosis of Adolescent SAPHO.

Authors:  Sudarshan Ravi; Abhishikta Dey; Damien McKay; Praneal Sharma; Sugendran Pillay
Journal:  Radiol Case Rep       Date:  2022-02-07

7.  Coexistence of Sjögren syndrome in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: A retrospective observational study.

Authors:  Lun Wang; Yanying Yu; Shuo Zhang; Wen Zhang; Chen Li
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

8.  Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Cutis Verticis Gyrata: Case Report and Review of Literature.

Authors:  Yifan Wang; Shan Wang; Liyun Zheng; Xiuli Wang; Hui Wang; Zhenyu Zhong; Siqi Liu; Xiaodong Zheng; Min Gao
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-07-23

Review 9.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

Review 10.  The Genetic Architecture of High Bone Mass.

Authors:  Celia L Gregson; Emma L Duncan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-29       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.